San Francisco, 14
November 2018: The global epilepsydrugs market is
expected to reach over USD 5,474.14 million by 2024, according to a new report
by Grand View Research, Inc. The rising government funding for the development
of new and effective drugs for the treatment of seizures is a high impact
rendering driver for the epilepsy drugs market growth. The American Epilepsy
Society (AES) in alliance with other organizations, such as American Academy of
Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding
for R&D activities and offer treatment line awareness trainingto the
physicians through different programs.
Furthermore, various awareness programs
conducted by organizations, such as the Epilepsy Foundation, the American
Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and
the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment
rates. This is expected to propel the market growth over the forecast
period.
Access
Research Report of Epilepsy Drugs Market@ www.grandviewresearch.com/industry-analysis/epilepsy-drugs-market
Further key findings from the study suggest:
· The second generation anti-epileptic drug
class is estimated to have over 30% market share in 2015 owing to the high
prescription rates, improved tolerability, and increased efficacy due to the
novel mechanisms of action of these drugs
· The third generation anti-epileptic drug
class is expected to witness the fastest growth with a CAGR of over 4% over the
forecast period. The major factors responsible for the growth of this segment
include the launch of high efficacy drugs with improved mechanism of action and
fewer side effects, and the awaited launch of new pipeline drugs.
· The growing need to improve the efficacy of
the existent drugs and the need to develop new and enhanced anti-epileptic
drugs to minimize the associated side-effects, such as dizziness, fatigue,
weight gain, and depression are the propelling factors expected to drive the
market growth over the forecast period
· North America dominated the market in terms
of revenue with over USD 2,000 million in 2015 owing to the presence of
well-established healthcare infrastructure, favorable government initiatives
directed at the betterment of the healthcare system, and the presence of
extensive research and development activities
· Asia Pacific is expected to witness
lucrative growth with a CAGR of around 4.5% over the forecast period owing to
the rising disposable income levels and the favorable, healthcare government
initiatives in emerging economies, such as India, Japan, and China
· Some major players of the epilepsy drugs
market include UCB Pharma Ltd., Sanofi S.A, Valeant Pharmaceuticals
International, Inc., Pfizer, Inc., Johnson & Johnson, Eisai Co., Ltd.,
Abbott Laboratories, Inc., Novartis AG, GlaxoSmithKline PLC., Sunovion
Pharmaceuticals, Inc., and Cephalon, Inc.
· Most of the key players are engaged in
strengthening their product portfolio to increase their market share. The
introduction of novel drugs is expected to foster the market penetration of
anti-epileptic drugs. For instance, in August 2015, the FDA-approved epilepsy
tablet, Aptiomby Sunovion Pharmaceuticals, Inc. for people suffering from
partial-onset seizures.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the
global epilepsy drugs market on the basis of treatment and region:
Global Epilepsy Drug market (Revenue, USD
Million, 2013 - 2024)
·
First generation anti-epileptic drug
·
Second generation anti-epileptic drug
·
Third generation anti-epileptic drug
Epilepsy Drugs Regional Outlook (Revenue,
USD Million, 2013 - 2024)
·
North America
o
U.S.
o
Canada
·
Europe
o
UK
o
Germany
·
Asia Pacific
o
India
o
China
·
Latin America
o
Brazil
·
MEA
o South Africa
Access Press Release of
Epilepsy Drugs Market@ www.grandviewresearch.com/press-release/global-epilepsy-drugs-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
